Skip to main content
Equibles
SCPX logo

SCPX · Scorpius Holdings, Inc.

Track SCPX — free

Use SCPX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about SCPX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.00 +0.00 (+0.00%) At close · Aug 14
Going-concern doubt — flagged Feb 17, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has determined that there is substantial doubt about the Company's ability to continue as a going concern within one year after the consolidated financial statements are issued.”
View the 10-Q filed Feb 17, 2026
Market Cap
$61,142
Shares
61.14M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.00 Open$0.00 Day$0.00–0.00 52W close$0.00–0.02 Avg vol 30d11K Short int298 · 0.0% float · 1.0d Short vol27% DataJul 2024–Aug 2026 Filing10-Q · Feb 17

Raw chart and full-history price indicators begin at the captured split on Jul 18, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Feb 17, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −88%
below
Price vs 50-day avg −57%
below
RSI (14) 47
neutral
MACD trend Positive
52-week position 4%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −9%
trailing
6-month return +400%
trailing
YTD return +400%
this year
Relative strength +386%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Distributing
-85% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -0.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Squeeze score 14
low risk · 0–100
Fundamentals
Fair
Revenue growth +281%
Y/Y
EPS growth +96%
Y/Y
Free cash flow $-26.9M
Balance sheet $5.9M
net debt
Quant / Vol
risk profile
Very High
Volatility 13327%
annualized · 1-yr
Max drawdown −100%
past year
ATR 180.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−88% Bearish
Price vs 50-day avg
−57% Bearish
RSI (14)
47 Neutral
MACD trend
Positive Bullish
52-week position
4% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Distributing
-85% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.00% of float · ▼ -0.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
2 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 4% Range high $0
vs 200-day avg -88% vs 50-day avg -57%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SCPX
Scorpius Holdings, Inc.
this stock
$61,142 +400.0% +281.2% — 0.0%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
2
% held
0.0%
Net QoQ
-775.7K sh
Top holder
Ground Swell Capital, LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
298
Days to cover
1.0d
Change
-1 sh
View
Short Volume
Short vol %
27%
As of
Aug 13, 2026
Short Total
View
Fails to Deliver
FTD shares
2
Value
$0
As of
Mar 6, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.8M
Net income (FY)
$-32.8M
EPS diluted
$-13.04
View
Filings
SEC Filings
Latest
8-K
Filed
Apr 24, 2026
This year
8
View
Exempt Offerings
Offering
$1.0M
Filed
Feb 18, 2025
View

Performance

Raw-price comparisons begin at the captured split on Jul 18, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
SCPX +100.0% -9.1% +400.0% +100.0% +400.0%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +99.6% -13.5% +386.2% +96.1% +386.2%
Key facts CIK 1476963 CUSIP 42237K508 Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)